Compare GH & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GH | ARCC |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.8B |
| IPO Year | 2018 | 2004 |
| Metric | GH | ARCC |
|---|---|---|
| Price | $78.47 | $18.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 10 |
| Target Price | ★ $120.05 | $21.60 |
| AVG Volume (30 Days) | 1.7M | ★ 7.5M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 10.66% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ 1.86 |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.30 | $5.77 |
| Revenue Next Year | $28.19 | $2.29 |
| P/E Ratio | ★ N/A | $9.69 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $17.40 |
| 52 Week High | $120.74 | $23.42 |
| Indicator | GH | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 45.82 |
| Support Level | $54.39 | $17.49 |
| Resistance Level | $114.53 | $20.28 |
| Average True Range (ATR) | 5.45 | 0.41 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 16.18 | 57.73 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.